Document is current
Any future updates will be listed below
-
Authors
Valerio, L. http://orcid.org/0000-0001-7723-7020
Giani, C.
Matrone, A.
Pontillo-Contillo, B.
Minaldi, E.
Agate, L.
Molinaro, E.
Elisei, R. http://orcid.org/0000-0002-5333-9257
-
Funding
Funding for this research was provided by:
PRIN 2017: New insights into the molecular signature of differentiated thyroid cancer: implications for diagnosis, prognosis and therapy (Prot. 2017YTWKWH)
Associazione Italiana per la Ricerca sul Cancro (IG 2018, Cod 21790)
Università di Pisa
- License Information
-
More Information
Article History
Received: 9 August 2022
Accepted: 25 January 2023
First Online: 21 February 2023
Declarations
:
: R.E. is a consultant for EISAI, IPSEN, Loxo and Bayer; the present study was not conditioned by this activity. The other authors have nothing to disclose.
: The study was approved by the local Ethical Committee (CEAVNO—Comitato Etico Area Vasta Nord-Ovest) (Prot. N. 11860) and the policy of the University Hospital. The study was conducted in accordance with the provisions of the Declaration of Helsinki (2013).
: All patients provided written informed consent to use their data for scientific purposes.
